Adds nine additional countries to the Company’s ongoing pivotal Phase 3 trial; Authorization granted in all EU countries requested Moleculin Biotech, Inc., a late-stage pharmaceutical
CStone Pharmaceuticals, a biopharmaceutical company dedicated to developing innovative cancer therapies, announced the submission of a Type II variation application to the European Medicines Agency (EMA) for sugemalimab.
According to Research by SNS Insider, The Virtual Clinical Trials Market Growth is Driven by Innovations in Digital Health Technologies, Increasing R&D Activities, and the
Fuel up with free Health Tech Insights
